RAPID OIA FOR DETECTION OF CHLAMYDIA AND GONORRHEA

Information

  • Research Project
  • 2429551
  • ApplicationId
    2429551
  • Core Project Number
    R44AI041939
  • Full Project Number
    1R44AI041939-01
  • Serial Number
    41939
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/30/1997 - 27 years ago
  • Project End Date
    3/31/1998 - 26 years ago
  • Program Officer Name
  • Budget Start Date
    9/30/1997 - 27 years ago
  • Budget End Date
    3/31/1998 - 26 years ago
  • Fiscal Year
    1997
  • Support Year
    1
  • Suffix
  • Award Notice Date
    9/30/1997 - 27 years ago
Organizations

RAPID OIA FOR DETECTION OF CHLAMYDIA AND GONORRHEA

DESCRIPTION: The goal of this project is to successfully develop and commercialize a simple, rapid, point of care test for the combined detection of chlamydia and gonorrhea from a single endocervical or male urethral swab sample. With this combined test, a physician will be capable of diagnosing chlamydia, gonorrhea, or co-infections and providing appropriate treatment at the time of a patient s first visit to the clinic. This will eliminate the need for subsequent patient contact to inform the test results and/or prescribe appropriate therapy. In Phase I on this project, BioStar, in collaboration with Dr. Edward Hook at the University of Alabama School of Medicine and Dr. Ellena Peterson at the University of California, Irvine, will conclude feasibility on the development of an assay for the detection of Neisseria gonorrhea. Feasibility will also be demonstrated for combining BioStar's current chlamydia assay with the assay for gonorrhea. The combined test will be developed using BioStar s patented Optical Immuno-Assay technology (OIA). Phase II of this project will focus on final optimization of the combined test and will bring the test through full development including assay transfer to manufacturing, scale-up of production, and conducting clinical trials for assay validation and FDA 510K submission.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R44
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG5
  • Study Section Name
  • Organization Name
    BIOSTAR, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    BOULDER
  • Organization State
    CO
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    80301
  • Organization District
    UNITED STATES